INT255068

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.38
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 1.59
Pain Relevance 0.21

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (GIP) small molecule metabolic process (GIP) extracellular region (GIP)
cytoplasm (GIP)
Anatomy Link Frequency
plasma 1
fat 1
GIP (Homo sapiens)
Pain Link Frequency Relevance Heat
Central nervous system 4 97.64 Very High Very High Very High
Neuropeptide 12 88.04 High High
agonist 8 72.44 Quite High
adenocard 6 49.52 Quite Low
potassium channel 6 39.12 Quite Low
chemokine 6 5.00 Very Low Very Low Very Low
headache 4 5.00 Very Low Very Low Very Low
rheumatoid arthritis 3 5.00 Very Low Very Low Very Low
substance P 3 5.00 Very Low Very Low Very Low
cytokine 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Diabetes Mellitus 226 93.92 High High
Hyperglycemia 16 85.56 High High
Myocardial Infarction 7 76.80 Quite High
Pressure And Volume Under Development 8 76.08 Quite High
Weight Gain 7 71.36 Quite High
Hypoglycemia 27 69.64 Quite High
Cardiovascular Disease 9 60.52 Quite High
Stroke 7 56.92 Quite High
Weight Loss 2 52.72 Quite High
Insulin Resistance 17 28.80 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The most important incretin hormones are the glucose dependent insulinotropic peptide (GIP) and GLP-1 (Effendic and Portwood 2004).
Positive_regulation (dependent) of GIP
1) Confidence 0.38 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.39 Pain Relevance 0
These new treatments include glucose dependent insulinotropic peptide (GIP) and glucagon like peptide-1 (GLP-1) (“incretin”) mimetics as well as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Positive_regulation (dependent) of GIP
2) Confidence 0.38 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.76 Pain Relevance 0.05
Plasma concentrations of both incretins increase within 5 to 15 min after meal ingestion: GLP-1 is primarily released by the ingestion of carbohydrate, fat and protein, whereas GIP is mainly liberated by the ingestion of carbohydrate and fat (Deacon 2005).
Positive_regulation (liberated) of GIP in fat
3) Confidence 0.35 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.30 Pain Relevance 0.08
Endogenous GLP-1 and GIP have half-lives of <2 minutes and 5–7 minutes, respectively, before they are rapidly degraded by the ubiquitous enzyme, DPP-4.16 DPP-4 is widely expressed in multiple tissues, including the central nervous system, kidney, lung, adrenal gland, liver, intestine, spleen, testis, and pancreas, as well as on the surfaces of lymphocytes and macrophages.16,17 As a result of DPP-4 degradative activity, intact and biologically active GLP-1 represents only 10%–20% of total plasma GLP-1.20 By inhibiting the enzymatic activity of DPP-4, circulating plasma levels of active GIP and GLP-1 can be increased 2-fold to 3-fold.2,21–23
Positive_regulation (increased) of GIP in plasma associated with central nervous system
4) Confidence 0.33 Published 2010 Journal Core Evidence Section Body Doc Link PMC2963920 Disease Relevance 0.15 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox